Hepatitis C virus therapy update 2013

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C virus (HCV) therapy through January 2013. We discuss current therapies, targets for new therapies, and what might be expected in this rapidly changing field. RECENT FINDINGS: Boceprevir-based and telaprevir-based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy for genotype 1 patients. New direct-acting antivirals (DAAs) are being developed and new antiviral drug targets are being explored. New combination treatment regimens are expected to emerge soon and there is hope for interferon-free regimens. SUMMARY: The standard of care for treatment of HCV genotype 1 changed dramatically with the approval of two new DAA drugs-telaprevir and boceprevir-for use in pegylated interferon-based and ribavirin-based triple therapy in mid-2011. Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection. However, persistent limitations to HCV treatment still exist for patients with prior treatment failure and comorbid conditions and patients on newer therapies suffer additional therapy-limiting side effects and drug-drug interactions. Genetic testing may provide some guidance but additional options for therapy are still needed for HCV. Many new drugs are currently under investigation and there is hope that effective and well tolerated interferon-free regimens may become a part of future therapy.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume29
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Hepacivirus
Interferons
Therapeutics
Antiviral Agents
Ribavirin
Genotype
Genetic Testing
Virus Diseases
Standard of Care
Drug-Related Side Effects and Adverse Reactions
Treatment Failure
Drug Interactions

Keywords

  • direct-acting antiviral
  • hepatitis C
  • polymerase inhibitor
  • protease inhibitor
  • triple therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatitis C virus therapy update 2013. / Casey, Lisa C.; Lee, William M.

In: Current Opinion in Gastroenterology, Vol. 29, No. 3, 05.2013, p. 243-249.

Research output: Contribution to journalArticle

@article{134a059902d14b709c887f9625887016,
title = "Hepatitis C virus therapy update 2013",
abstract = "PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C virus (HCV) therapy through January 2013. We discuss current therapies, targets for new therapies, and what might be expected in this rapidly changing field. RECENT FINDINGS: Boceprevir-based and telaprevir-based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy for genotype 1 patients. New direct-acting antivirals (DAAs) are being developed and new antiviral drug targets are being explored. New combination treatment regimens are expected to emerge soon and there is hope for interferon-free regimens. SUMMARY: The standard of care for treatment of HCV genotype 1 changed dramatically with the approval of two new DAA drugs-telaprevir and boceprevir-for use in pegylated interferon-based and ribavirin-based triple therapy in mid-2011. Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection. However, persistent limitations to HCV treatment still exist for patients with prior treatment failure and comorbid conditions and patients on newer therapies suffer additional therapy-limiting side effects and drug-drug interactions. Genetic testing may provide some guidance but additional options for therapy are still needed for HCV. Many new drugs are currently under investigation and there is hope that effective and well tolerated interferon-free regimens may become a part of future therapy.",
keywords = "direct-acting antiviral, hepatitis C, polymerase inhibitor, protease inhibitor, triple therapy",
author = "Casey, {Lisa C.} and Lee, {William M.}",
year = "2013",
month = "5",
doi = "10.1097/MOG.0b013e32835ff972",
language = "English (US)",
volume = "29",
pages = "243--249",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hepatitis C virus therapy update 2013

AU - Casey, Lisa C.

AU - Lee, William M.

PY - 2013/5

Y1 - 2013/5

N2 - PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C virus (HCV) therapy through January 2013. We discuss current therapies, targets for new therapies, and what might be expected in this rapidly changing field. RECENT FINDINGS: Boceprevir-based and telaprevir-based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy for genotype 1 patients. New direct-acting antivirals (DAAs) are being developed and new antiviral drug targets are being explored. New combination treatment regimens are expected to emerge soon and there is hope for interferon-free regimens. SUMMARY: The standard of care for treatment of HCV genotype 1 changed dramatically with the approval of two new DAA drugs-telaprevir and boceprevir-for use in pegylated interferon-based and ribavirin-based triple therapy in mid-2011. Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection. However, persistent limitations to HCV treatment still exist for patients with prior treatment failure and comorbid conditions and patients on newer therapies suffer additional therapy-limiting side effects and drug-drug interactions. Genetic testing may provide some guidance but additional options for therapy are still needed for HCV. Many new drugs are currently under investigation and there is hope that effective and well tolerated interferon-free regimens may become a part of future therapy.

AB - PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C virus (HCV) therapy through January 2013. We discuss current therapies, targets for new therapies, and what might be expected in this rapidly changing field. RECENT FINDINGS: Boceprevir-based and telaprevir-based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy for genotype 1 patients. New direct-acting antivirals (DAAs) are being developed and new antiviral drug targets are being explored. New combination treatment regimens are expected to emerge soon and there is hope for interferon-free regimens. SUMMARY: The standard of care for treatment of HCV genotype 1 changed dramatically with the approval of two new DAA drugs-telaprevir and boceprevir-for use in pegylated interferon-based and ribavirin-based triple therapy in mid-2011. Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection. However, persistent limitations to HCV treatment still exist for patients with prior treatment failure and comorbid conditions and patients on newer therapies suffer additional therapy-limiting side effects and drug-drug interactions. Genetic testing may provide some guidance but additional options for therapy are still needed for HCV. Many new drugs are currently under investigation and there is hope that effective and well tolerated interferon-free regimens may become a part of future therapy.

KW - direct-acting antiviral

KW - hepatitis C

KW - polymerase inhibitor

KW - protease inhibitor

KW - triple therapy

UR - http://www.scopus.com/inward/record.url?scp=84876286638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876286638&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32835ff972

DO - 10.1097/MOG.0b013e32835ff972

M3 - Article

C2 - 23563981

AN - SCOPUS:84876286638

VL - 29

SP - 243

EP - 249

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -